News Sentiment

IRD sentiment intelligence

Opus Genetics, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 22 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.92 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

76/100 classification confidence.

Company focus 13

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-7.3% over one week, -3.0% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Price to earnings forward of Opus Genetics, Inc. – NASDAQ:IRD

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 76/100 classification
One-week reaction -7.3% Price reacting lower
Trend fit Trend active -3.0% over four weeks
Fair value 73.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 5
Neutral 14
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 13
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
simplywall.st 4
TradingView 2
Seeking Alpha 2
The Globe and Mail 1
Simply Wall Street 1
MarketBeat 1
Stock Titan 1

Event Lens

What the news is about

Classified themes
Earnings 12
Market update 7
Analyst action 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-22 of 22
Simply Wall Street Direct company coverage

Opus Genetics (Nasdaq:IRD) - Stock Analysis

Opus Genetics (Nasdaq:IRD) is a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases. The stock is currently trading at US$5.00, with analysts setting a price target of US$10.07, indicating it is undervalued. The company faces risks su

Tone
Positive 61/100
Event
Analyst action
Published
26 Apr 2026 23:08
Source
Simply Wall Street
MarketBeat Direct company coverage

Oppenheimer Initiates Coverage on Opus Genetics (NASDAQ:IRD)

Oppenheimer has initiated coverage on Opus Genetics (NASDAQ:IRD) with an "outperform" rating and a $10.00 price target, suggesting a potential upside of nearly 99%. This comes amidst several other analyst "buy" or "strong-buy" ratings and significant insider and institutional buy

Tone
Positive 81/100
Event
Analyst action
Published
14 Mar 2026 12:40
Source
MarketBeat
Stock Titan Direct company coverage

OCUP Stock Price, News & Analysis

Ocuphire Pharma, Inc. (OCUP) historically focused on clinical-stage ophthalmic therapies before combining with Opus Genetics, Inc. The combined entity, now operating as Opus Genetics, Inc. and trading under "IRD" on Nasdaq, focuses on gene therapies for inherited retinal diseases

Tone
Positive 72/100
Event
Market update
Published
25 Apr 2025 19:27
Source
Stock Titan
Market source Direct company coverage

Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal

Ocuphire Pharma, Inc. announced an all-stock acquisition of Opus Genetics, Inc., a clinical-stage gene therapy company for inherited retinal diseases (IRDs). This merger will shift Ocuphire's focus to gene therapy, with the combined company being renamed Opus Genetics and trading

Tone
Neutral 50/100
Event
Deals and strategy
Published
23 Oct 2024 04:10
Source
Market source
Market source Direct company coverage

Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics

Ocuphire Pharma has merged with Opus Genetics in an all-stock transaction, forming a new biotech company focused on gene therapies for inherited retinal diseases. The combined entity will be renamed Opus Genetics, Inc. and trade under the ticker 'IRD', with plans for significant

Tone
Neutral 50/100
Event
Market update
Published
23 Oct 2024 00:00
Source
Market source